Sanofi has discontinued its Phase 3 MOBILIZE study of Sanofi riliprubart in chronic inflammatory demyelinating polyneuropathy after an interim analysis showed the trial was unlikely to demonstrate sufficient efficacy, according to a June 10, 2026 update. The decision followed an
